# Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

Study · id `cardio:ct-nct06772168` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06772168](<https://clinicaltrials.gov/study/NCT06772168>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06772168

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.

## Technical summary

Registry record NCT06772168. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-19 (actual); primary completion 2026-11-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT06772168, source copy `cardio:ctgov-nct06772168-2026-01-15`, retrieved 2026-10-26)
- Started: 2024-04-19 (actual) (ClinicalTrials.gov record NCT06772168, source copy `cardio:ctgov-nct06772168-2026-01-15`, retrieved 2026-10-26)
- Primary completion: 2026-11-04 (anticipated) (ClinicalTrials.gov record NCT06772168, source copy `cardio:ctgov-nct06772168-2026-01-15`, retrieved 2026-10-26)
- Completion: 2027-02-01 (anticipated) (ClinicalTrials.gov record NCT06772168, source copy `cardio:ctgov-nct06772168-2026-01-15`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06772168, source copy `cardio:ctgov-nct06772168-2026-01-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06772168-2026-01-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
- Condition: Dyslipidemia
- Condition: Type 2 Diabetes
- Intervention (Drug): CMG190303(Dapagliflozin/Rosuvastatin)
- Intervention (Drug): Comparator 1: Dapagliflozin/Rosuvastatin placebo
- Intervention (Drug): Rosuvastatin/Dapagliflozin placebo
- Lead sponsor: CMG Pharmaceutical Co. Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 3ca5675b8d938d7a79146c02414a207caf5726fbe0eb12649c643832ad706801
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
